

# *POKROKY V NEUROVĚDÁCH 2019*

## *Iontové kanály excitabilních buněk I.*

### ***Ionotropní glutamátové receptory***

Prof. Ladislav Vyklický

13:00 – 13:40 (35+5)

### ***Genetika ionotropních glutamátových receptorů ve vztahu k neurodevelopmentálním a neuropsychiatrickým onemocněním***

Dr. Aleš Balík

13:40 – 14:20 (35+5)

### ***Synaptická plasticita: Mechanismy LTP a LTD v hipokampu***

Dr. Miloslav Kořínek

14:20 - 15:00 (35+5)

### ***Excitotoxicita***

Dr. Tereza Smejkalová

15:00 - 15:40 (35+5)

### ***Napěťově aktivované iontové kanály a kanálopatie***

Dr. Jan Krůšek

15:40 - 16:20 (35+5)

# *Ionotropní glutamátové receptory*

---

*POKROKY V NEUROVĚDÁCH 2019*


*Prof. MUDr. Ladislav Vyklický DrSc*

*Oddělení buněčné neurofyziologie  
Fyziologický ústav AVČR  
Vídeňská 1083*

[Ladislav.Vyklicky@fgu.cas.cz](mailto:Ladislav.Vyklicky@fgu.cas.cz)

## Newtonův gravitační zákon


$$F_g = G \frac{m_1 m_2}{r^2}$$



**Isaac Newton** 1643 – 1727

## Ekvivalence energie a hmotnosti

$$E = mc^2$$




**Albert Einstein** 1879 – 1955  
1921 - Nobelova cena za fyziku

## Kvantověmechanický model atomu




**Louis Victor Pierre Raymond vévoda de Broglie** 1892 – 1987  
1929 – Nobelova cena za fyziku - objev vlnově korpuskulárního dualismu částic



**Linus Carl Pauling** 1901 – 1994  
1954 - Nobelova cena za výzkum podstaty chemické vazby




**Max Born** 1882–1970  
1954 - Nobelova cena za kvantovou mechaniku



**Walther Bothe** 1882 – 1970  
1954 - Nobelova cena za kvantovou mechaniku


# *Historické poznámky*

-220



**Jan E. Purkyně** (1787-1869)

-152



Glutamate  
was  
discovered  
and  
identified  
in 1866

-118



**Kikunae Ikeda** (1864 – 1936)

-100



**1921 Otto Loewi** (1873-1961)

1936 - Nobelova cena za fyziologii a medicínu

-66



**Takashi Hayashi** 1897-1969




Keio Journal of Medicine  
Vol. 3, No. 4, December, 1954

## EFFECTS OF SODIUM GLUTAMATE ON THE NERVOUS SYSTEM

TAKASHI HAYASHI

*Department of physiology, School of Medicine,  
Keio University*

(Received on December 25th, 1954)





# Synapse


Lidský mozek obsahuje  
50,000,000,000 neuronů  
( $5 \cdot 10^{10}$ ).


Na neuronu může být až  
200,000 synapí

$10^{13}$  synaptických kontaktů  
v mozku člověka




Kyselina glutamová





$180 \text{ \AA}$


$18 \text{ nm}$   
( $10^{-9} \text{ m}$ )



O

$6 \text{ \AA}$


$1.0 \times 10^{-10} \text{ m}$



$\Leftrightarrow$



$18 \mu\text{m}$   
( $10^{-6} \text{ m}$ )

Pór = 0.6 mm  
vlas



18 nm  
( $10^{-9}$  m)


6 Å  
 $1.0 \times 10^{-10}$  m



18 µm  
( $10^{-6}$  m)


# *Excitační synapse*

200 000  
synapsi




Glie


Presynaptický neuron



Postsynaptický neuron




# *Uvolňování glutamátu z presynaptické terminály*



1 mM glutamátu na dobu 1 ms

# *Excitační postsynaptické proudy*



# Podjednotkové složení ionotropních glutamátových receptorů

## Ionotropní glutamátové receptory

**Podjednotka      Gen      Chromozóm**

**AMPA ( $\alpha$ -amino-3-hydroxyl-**

**5-methyl-4-isoxazole-propionate)**


|       |       |          |
|-------|-------|----------|
| GluA1 | GRIA1 | 5q33     |
| GluA2 | GRIA2 | 4q32-33  |
| GluA3 | GRIA3 | Xq25-26  |
| GluA4 | GRIA4 | 11q22-23 |

**Kainát**

|       |       |              |
|-------|-------|--------------|
| GluK1 | GRIK1 | 21q21.1-22.1 |
| GluK2 | GRIK2 | 6q16.3-q21   |
| GluK3 | GRIK3 | 1p34-p33     |
| GluK4 | GRIK4 | 11q22.3      |
| GluK5 | GRIK5 | 19q13.2      |

**NMDA ( $N$ -methyl-D-aspartát)**

|        |        |             |
|--------|--------|-------------|
| GluN1  | GRIN1  | 9q34.3      |
| GluN2A | GRIN2A | 16p13.2     |
| GluN2B | GRIN2B | 12p12       |
| GluN2C | GRIN2C | 17q24-q25   |
| GluN2D | GRIN2D | 19q13.1qter |
| GluN3A | GRIN3A | 9q31.1      |
| GluN3B | GRIN3B | 19p13.3     |



### ORIGIN


```

1 mkpraeccsp kfwlqlavla vsgsrarsqk sppsigiavi lvgtsdevai kdahekddfh
61 hlsvvprvel vammnetdplks iittricdlims drkiqgvvfa dddtqeaaq ildfisaqtl
121 tpilgihggs smimadkdes smffqfgpsi eqqasvmlni meeiydwifys ivtvyfpqyq
181 dfvnkirsti ensfvwgwele evlfldmsld dgdsksiqnq kklqspis yctkeeatyi
241 fevansvglt gygytwivps lvagdtdtvp aefptglisy svvedwyglp arvrdgaii
301 ttaasdmlse hsfipecpkss cynthekrii qsnmlnryli nvtfegrnlis fsedgyqmhp
361 klviillnke rkwervgkwk dkslqmkyyv wprmcpcetee qeddhsivt leeapfvive
421 svdplsgtcm rntvpcqkri vtenktdeep gyikkcckgf cidilkkisk svkftydlyl
481 vtngkhgkki ngtwngmige vvmkraymav gsltineers evvdfsvpvp etgisvmvsr
541 sngtvspasf lepfadsdvww mmfvmllivs avavfvfeyf spvgynrcla dgrepqgsf
601 tigkaillw glvfnnsvpv qnpkgttski mvsvwaffava iflaysyntanl aafmiqueeyv
661 dqvsglsdkk fqrpnmdfssp frfgrtvpgns ternirnnya emhavgmkfn qrgvvdalls
721 lktgkldafi ydaavlnyma grdegcklv igsgkvfast gygiaiqkds gwkrqvdlai
781 lqlfgdgeme elealwlgti chneknevms sqldidnmag vfymlgama lslitficeh
841 lfywqfrhcf mgvcsgkpgm vfsisrgiys cihgvaeier qsvmnspstat mnntnhsnilr
901 llrtaknman lsgvngspqs aldfirress vydisehrss fthsdcksyn nppceenlfs
961 dyisevertf gnlqlkdsnv yqdhyhhhr phsigsassi dglydcndpp fttqrsrsisk
1021 kpldiglpss khsqldlyg kfksfsdryv ghddlrstdv sdisthtvty gniegakr
1081 rkqqykdslk krpasaksrr efdeielayr rrpprspdhn ryfrdkeglr dfyldqfrtk
1141 ensphwhevhd ltdiykersd dfkrdsrvsgg gpctnrshik hgtgdkgvv svgpapwekn
1201 ltnvewedrs ggnfcrcscps khnysttv gqnsgraci rceackagn lydisednsl
1261 qeldqpaapv avtsnasttk yqpsptnska qkknrnkllr qhsydtfvdl qkeeaalapr
1321 svslkdkgmf mdgspyahmf emsagestfa nnkssvptag hhhhnnpggg ymlskslypd
1381 rvtqnpfipt fgdddqcllhg sksyffrqpt vagaskarpd fralvtnkpv vsalhgavpa
1441 rfqkdicign qsnpcvpnnk nprafngssn ghvyeklssi esdv

```



# Alternativní sestřih




GluN 1-1a  
GluN 1-1b  
GluN 1-2a  
GluN 1-2b  
GluN 1-3a  
GluN 1-3b  
GluN 1-4a  
GluN 1-4b




GluN 2A  
GluN 2B  
GluN 2C  
GluN 2D

GluN 3A  
GluN 3B






*.. to be or not to be ....*




*Pamatujete si tento obrázek?*



# Long term potentiation of synaptic transmission (LTP)





# *Long term potentiation of synaptic transmission (LTP)*



# Odstranění glutamátu

Glie



*Pamatujete si jméno tohoto vědce?*




*Pamatujete si jméno tohoto vědce?*



**Takashi  
Hayashi**


# *Excitotoxicita*

Glutamát  
?? <100 nM ... 100  $\mu$ M  
Hodiny až dny




# *Excitotoxicity*

Control



Glutamate 30 min



# *"Glutamátergní" teorie vzniku:*

## *Výrazná neurodegenerace*

- Alzheimerova choroba
- Důsledky mozkové příhody
- Tramatické poškození mozku
- Parkinsonova choroba
- Tardivní dyskinezie
- Huntingtonova choroba
- Amyotrofická laterální skleroza
- Olivopontocerebellar degenerace
- AIDS
- Alergická encefalomyelitida

## *Další*

- Epilepsie
- Anxieta
- Deprese
- Schizofrenie
- Chronická bolest
- Léková závislost


# Human diseases and mutations in GRIN genes

| GluN2B mut. | Genotype  | Phenotype  | Age of onset    | Source  |
|-------------|-----------|--|-----------------|---|
| P553L       | c.1658C>T | ID, hypotonia  | Early postnatal | (de Ligt et al., 2012)                            |
| V558I       | c.1672G>A | ID   | -               | (Hamdan et al., 2014)<br>(Lelieveld et al., 2016) |
| W607C       | c.1821G>A | ID, DD, dysmorphic features                                  | -               | (Yavarna et al., 2015)                            |
| N615I       | c.1844A>G | WS, ID   | 7 weeks         | (Lemke et al., 2014)                              |
| V618G       | c.1853T>C | ID, WS, Epi-encephalopathy                                   | 4 months        | (Lemke et al., 2014)                              |
| S628F       | c.1883G>T | ID, DD, Epi-encephalopathy                                   | -               | (Platzer et al., 2017)                            |
| E657G       | c.1970A>G | ID, DD   | -               | (Platzer et al., 2017)                            |
| G820E       | c.2459C>T | ID, microcephaly   | Early postnatal | (Hamdan et al., 2014)                             |
| G820A       | c.2459G>A | ID, DD, DMD, ES, ASD   | months          | (Platzer et al., 2017)                            |
| M824R       | c.2471T>G | ID, DD, microcephaly, Rett-like picture, Fpi activity on EEG | months          | (Zhu et al., 2015)                                |
| L825V       | c.2473T>G | ASD  | -               | (Awadalla et al., 2010)<br>(Swanger et al., 2016) |

ID - intellectual disability; DD - developmental delay; WS - West syndrome; Epi - epilepsy and/or seizures, infantile spasms; ASD - Autism Spectrum Disorder; DMD - Dyskinetic movement disorder; ES - epileptic spasms; GCVL - generalised cerebral volume loss

**A**

|    | pre-M1   | M1   | M2   |       |
|----|--|--|--|-------|
| N1 | (549) STLDSFMQP <span style="background-color: yellow;">FQSTLWLLVGLSVHVVAVMLYLLDR</span>   |  | (604) SSAMWF <span style="background-color: yellow;">SWGVLNSGIGEGAP</span>   | NTD   |
| 2A | (544) VSPSAFLEPFSASVVMMFVMLLIVS <span style="background-color: yellow;">IAVFVFE</span>   |  | (602) GKAI <span style="background-color: yellow;">WLWGLVFNNNSVPVQNP</span>  | preM1 |
| 2B | (545) VSPSAFLE <span style="background-color: red; color: black;">PFSAD</span> <span style="background-color: yellow;">VVVMMFVMLLIVS</span> AVAVFVFE     |  | (603) GKAI <span style="background-color: yellow;">WLWGLVFNNNSVPVQNP</span>  | M2    |
| 2C | (542) VSPSAFLEPYSPA <span style="background-color: yellow;">VVVMMFVMCLTVVAITVFMFE</span>   |  | (600) GKS <span style="background-color: yellow;">VWLWALVFNNNSVPPIENP</span> | M3    |
| 2D | (572) VSPSAFLEPYSPA <span style="background-color: yellow;">VVVMMFVMCLTVVAITVFMFE</span>   |  | (630) GKS <span style="background-color: yellow;">IWLWALVFNNNSVPVENP</span>  | M4    |
|    |  | M3   |  | CTD   |
| N1 | (625) RSFSARILGMVWAGFAMIIVAS <span style="background-color: yellow;">YTANLAFLVLD</span> R  | (808) LT <span style="background-color: yellow;">FENMAGVFMLVAGGIVAGIFLIFIE-IAYK</span>   |  |       |
| 2A | (623) KGTTSKIMVSVWAFFAVIF <span style="background-color: yellow;">FLASYTANLAFLMIQE</span> E  | (812) LDIDN <span style="background-color: yellow;">MAGVFYMLAAAMALSITFIWEHLFYW</span>  |  |       |
| 2B | (624) KGTT <span style="background-color: red; color: black;">S</span> KIMVSVWAFFAVIF <span style="background-color: yellow;">FLASYTANLAFLMIQE</span> EY | (813) LDIDN <span style="background-color: yellow;">MAGVFYMLGAAMALSITFICEHLFYW</span>  |  |       |
| 2C | (621) RGTTSKIMVLVWAFFAVIF <span style="background-color: yellow;">FLASYTANLAFLMIQE</span> QY   | (810) LDIDN <span style="background-color: yellow;">MAGVFYMLLVAMGLALLVFAWEHLVYW</span>   |  |       |
| 2D | (651) RGTTSKIMVLVWAFFAVIF <span style="background-color: yellow;">FLASYTANLAFLMIQE</span> EY   | (840) LD <span style="background-color: yellow;">IDN<span style="background-color: yellow;">MAGVFYMLLVAMGLLLLFAWEHLVYW</span></span> |  |       |



# *Intellectual disability*

Estimates of the prevalence of ID range widely, from **9 to 40 per 1,000 (1-4%)**



**Intellectual disability (ID)**, also known as **general learning disability**, and **mental retardation (MR)**, is a generalized neurodevelopmental disorder characterized by significantly impaired intellectual and adaptive functioning. It is defined by an IQ score under 70 in addition to deficits in two or more adaptive behaviors that affect everyday, general living.

- Mild ID (IQ 50–69)**
- Moderate ID (IQ 35–49)**
- Severe or profound ID**

***Some of the early signs can include:***

- Delays in reaching or failure to achieve milestones in **motor skills development** (sitting, crawling, walking)
- **Slowness learning to talk** or continued difficulties with speech and language skills after starting to talk
- Difficulty with **self-help and self-care** skills (e.g., getting dressed, washing, and feeding themselves)
- Poor planning or **problem solving abilities**
- **Behavioral and social problems**
- **Failure to grow intellectually** or continued infant-like behavior
- Problems keeping up in school
- **Failure to adapt or adjust to new situations**
- **Difficulty understanding and following social rules**

# Autism




Most recent reviews tend to estimate a prevalence of **1-2 per 1,000 for autism** and **6 per 1,000 for ASD**

Autism is a **developmental disorder** characterized by troubles with **social interaction** and **communication**, and by **restricted and repetitive behavior**. Parents usually notice signs in the first **two or three years of their child's life**. These signs often develop gradually, though some children with autism reach their developmental milestones at a normal pace and then worsen.



**Paul Eugen Bleuler** (1857 – 1939) Swiss psychiatrist - he started using the term around 1911



**Hans Asperger** (1906-1980)  
Austrian pediatrician, medical theorist, and medical professor - ... his work on “autistic psychopathy”... 400 children with autistic psychopathy.



**Leo Kanner** (1894 – 1981)  
Austrian-American psychiatrist  
- Autistic disturbances of affective contact. Nerv Child **1943; 2:217–50.**

# ...kde jsou geny, tam jsou problémy ...

## Family

| Subunit | Gene | Chromosome |
|---------|------|------------|
|---------|------|------------|

### **AMPA ( $\alpha$ -amino-3-hydroxyl-5-methyl-4-isoxazole-propionate)**


|       |       |          |
|-------|-------|----------|
| GluA1 | GRIA1 | 5q33     |
| GluA2 | GRIA2 | 4q32-33  |
| GluA3 | GRIA3 | Xq25-26  |
| GluA4 | GRIA4 | 11q22-23 |

## Kainate


|       |       |              |
|-------|-------|--------------|
| GluK1 | GRIK1 | 21q21.1-22.1 |
| GluK2 | GRIK2 | 6q16.3-q21   |
| GluK3 | GRIK3 | 1p34-p33     |
| GluK4 | GRIK4 | 11q22.3      |
| GluK5 | GRIK5 | 19q13.2      |

### **NMDA ( $N$ -methyl-D-aspartate)**

|               |               |              |
|---------------|---------------|--------------|
| GluN1         | GRIN1         | 9q34.3       |
| GluN2A        | GRIN2A        | 16p13.2      |
| <b>GluN2B</b> | <b>GRIN2B</b> | <b>12p12</b> |
| GluN2C        | GRIN2C        | 17q24-q25    |
| GluN2D        | GRIN2D        | 19q13.1qter  |
| GluN3A        | GRIN3A        | 9q31.1       |
| GluN3B        | GRIN3B        | 19p13.3      |



Leucin



Valin

GluN2B (L825V)



vfymlgaama


#### ORIGIN

```

1 mkpraeccsp kfwlvlavla vsgsrarsqk sppsigiavi lvgtsdevai kdahekddfh
61 hlsvvprvel vammtdipks iitriccdlms drkiqgvvfa ddtdqeaiaq ildfisaqt1
121 tpiilgihggs smimadkdes smffqfgpsi eqqasvmlni meeiydwyifs ivtvyfpqyq
181 dfvnkirsti ensfvwgwele dgdskiqnql kklqpiill yctkeateyi
241 fevansvglt gygytivwps lvaagtdtvp aefptglisy sydewdyglp arvrdgaiii
301 ttaasdmlse hsfipecpkss cynthekriy qsnmlnryli nvtfegrnlis fsedgyqmhp
361 klviillnke rkwervgkwk dksslqmkyyv wprmcpcetee qeddhsivt leeapfvive
421 svdplsgtcm rntvpcqkri vtenktdeep gyikkcckgf cidilkkisk svkftydlyl
481 vtngkhgkki ngtwngmige vvmkraymav gsltineers evvdfsdpfi etgisvmvsr
541 sngtvpsaf lepfadsdvwm mmfvmllivs avavfvfeyf spvgynrcia dgrepqgsf
601 tigkaiww glvfnnsvpv qnpkgttski mvsswaffav iflasytanl aafmiqueeyv
661 dqvsglsdkk fqrpnfdspf frfgrtvpgns ternrnrrna emhaymgkfn qrgvddalls
721 lktgkldafi ydaavlnyma grdegcklv igsgkvlast gygiaikdks gwkrqvndlai
781 lqlfgdgeme elealwlgti chneknevms sqldidnmag vfymlgaama lslitficheh
841 lfywqfrhcf mgvcsgkpgm vfsisrgiys cihgvaeier qsvmnspstat mnnthsnilr
901 llrtaknman lsgvngspqs aldfirress vydisehrss fthsdcksyn nppceenlfs
961 dyisevertf gnlqlkdsnv yqdhyhhhr phsigsassi dglydcndpp fttqrsrsisk
1021 kpldiglpss khsqldlyg kfksfksdryv sdisthtvty gniegakr
1081 rkqqykdslk krpasaksrr efdeielayr rrpprspdhk ryfrdkeglr dfyldqfrtk
1141 ensphwehvd ltdiykersd dfkrdsrvsgg gpctnrshik hgtgdkgvv svgpapwekn
1201 ltnvewedrs ggnfcrcscps khnysttv gqnsgrqaci rceackkagn lydisednsl
1261 qeldqpaapv avtsnasttk yqpsptnska qkknrnklrr qhsydtfvdl qkeeaalapr
1321 svslkdkgrf mdgspyahmf emsagestfa nnkssvptag hhhhnnpggg ymlskslypd
1381 rvtqnpfipt fgddqcllhg sksyffrqpt vagaskarpd fralvtnkpv vsalhgavpa
1441 rfqkdicign qsnpcvpnnk nprafngssn ghvyeklssi esdv

```






*Surface expression*

*Functional properties:*


- i. agonist affinity*
- ii. receptor desensitization*
- iii. probability of opening*

# „Patch-clamp“ technika


Recombinant receptors  
HEK293 (GluN1/GluN2B)



Hippocampal cultures



Erwin Neher




Bert Sakmann

NP... Medicine 1991




Patch-clamp amplifier

# „Patch-clamp“ a rychlá aplikace látek




# „Patch-clamp“ a rychlá aplikace látek



# Pravděpodobnost otevření a desensitizace


A

L825V MK801




a


WT  $P_o = 10\%$



D




0.1 nA  
1 s



L825V  $P_o = 1.4\%$

B

V558I MK801



$D = 72\%$

a

b

MK801


WT  
10%

0.2 nA  
10 s


0.2 nA  
0.1 s

$P_o = 0.6\%$

# Acute „non-genomic“ action of steroids



Anesthetic Effect of Steroid Hormones,  
*Proc. Soc. Exptl. Biol. Med.* **46**, 116-21 (1941)







**H. H. B. Selye  
(1907 - 1982)**

The Austrian-Hungarian endocrinologist was born in Vienna and graduated at Prague's German Faculty of Medicine. ... is known as "the father of stress,,,"


# Steroids and NMDA receptors

## Neurosteroids:

- are synthesized *de novo* in the CNS
- can reach a high local concentrations
- have a direct non-genomic effect



# *Steroids can compensate NMDA receptor malfunction*



*Věda je velké dobrodružství*



*Děkuji za pozornost*